npj Regenerative Medicine - Deer antler ASCs exosomes ameliorate osteoarthritis via miR-140/MMP13 axis-mediated dual modulation of inflammation and cartilage regeneration

Objective Matrix metalloproteinase 13 (MMP13) is an extracellular matrix protease that affects the progression of atherosclerotic plaques and arterial thrombi by degrading collagens, modifying…

Cartilage in the knee and temporomandibular joint (TMJ) rely on subchondral bone for joint homeostasis, whereby osteoarthritis (OA) causes degeneration. In the knee, suppression of osteocytic perilacu...

Guo et al. identify MAVS as a critical driver of OA by promoting NF-κB-dependent MMP3 and MMP13 expression and ECM degradation in chondrocytes. Genetic deletion and pharmacological inhibition of MAVS alleviate OA phenotypes, highlighting that MAVS signaling may be a potential therapeutic target for OA treatment.

medRxiv - The Preprint Server for Health Sciences

Features: *Note:  (1) The orignal packing comes with plastic tray only. There is no outer color box designed for this figure. (2) We would ship the item with loose pack while the platic tray would be removed for convenience in shipment.  This is a 1:1 KO version of MPM11 without modification. Pros: Almost no difference

ABSTRACT Osteoarthritis (OA) is a widespread degenerative joint condition marked by progressive cartilage breakdown, and a chronic inflammatory microenvironment, where conventional therapies largely fail to halt disease progression. To address this unmet need, an intra-articularly implantable, disease-responsive scaffold was developed for combinatorial treatment to simultaneously combat inflammation and promote anabolism. The system is based on an MMP13-sensing peptide-modified type II collagen scaffold engineered for controlled release of celecoxib (CXB), an anti-inflammatory agent, and fibroblast growth factor-18 (FGF-18), a pro-anabolic growth factor. Comprehensive physicochemical characterization confirmed the scaffold's porous structure, successful conjugation of the responsive peptide, and MMP13-dependent drug release. In vitro studies demonstrated excellent biocompatibility, potent anti-inflammatory effects, and enhanced chondrogenic matrix production under IL-1β stimulation. When evaluated the rat OA cartilage defect model, the dual-drug scaffold significantly suppressed inflammation and subchondral bone damage, while promoting early matrix anabolism, and outperforming the control group. This MMP13-sensing scaffold represents a precision medicine strategy for OA therapy, enabling intelligent, microenvironment-driven drug delivery to disrupt the degenerative cycle and facilitate synergistic early-stage anti-inflammatory and anabolic effects.

Recent research identifying the underlying mechanisms of peripheral neuropathy, or nerve damage, has raised the prospect that drug therapies can be developed for the treatment of this condition, which causes pain, numbness and/or tingling in the hands and feet. Source: Scientist identifies mechanism underlying peripheral neuropathy: Discovery raises prospect of treatments for common painful condition

Modifications enhancing degradation resistance and albumin affinity enabled the delivery of an siRNA conjugate silencing MMP13 to guinea pig and murine arthritic joints, improving therapeutic outcomes...